Brief: Cardiff Oncology Receives FDA Orphan Drug Designation For Onvansertib In Chronic Myelomonocytic Leukemia
21/10/2026 23:09
BRIEF-Cardiff Oncology Receives FDA Orphan Drug Designation For Onvansertib In Chronic Myelomonocytic Leukemia Oct 21 (Reuters) - Cardiff Oncology, Inc. CRDF.O:
CARDIFF ONCOLOGY RECEIVES FDA ORPHAN DRUG DESIGNATION FOR ONVANSERTIB IN CHRONIC MYELOMONOCYTIC LEUKEMIA
CARDIFF ONCOLOGY - ONVANSERTIB BEING EVALUATED IN PHASE 1 STUDY FOR RELAPSED/REFRACTORY CMML
CARDIFF ONCOLOGY - ONVANSERTIB SHOWED PRELIMINARY EFFICACY IN 40% OF MYELOPROLIFERATIVE CMML PATIENTS
Source text: ID:nGNX80svnF
Further company coverage: CRDF.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cardiff Oncology
See all newsBrief: Cardiff Oncology Receives FDA Orphan Drug Designation For Onvansertib In Chronic Myelomonocytic Leukemia
Corrected: Cardiff Oncology Q2 operating expenses fall on lower R&D costs
Cardiff Oncology Inc expected to post a loss of 16 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Cintas, Veradermics
Cardiff Oncology sinks on direct equity offering